Effective treatment of esophogeal adenocarcinoma using triciribine and related compounds
US8178502B2 · kind B2 · utility
0Cited by
0References
21Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 8, 2008 |
| Grant date | May 15, 2012 |
| Priority date | — |
| Expiry date | Jan 19, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/912
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.